Last reviewed · How we verify
Cessation of antibiotics
Cessation of antibiotics is a Small molecule drug developed by Brigham and Women's Hospital. It is currently in Phase 3 development for De-escalation or cessation of antibiotic therapy in appropriate clinical contexts to reduce antibiotic-associated adverse effects. Also known as: Stop antibiotics.
Cessation of antibiotics allows restoration of the patient's natural microbiome and reduces antibiotic-associated adverse effects.
Cessation of antibiotics allows restoration of the patient's natural microbiome and reduces antibiotic-associated adverse effects. Used for De-escalation or cessation of antibiotic therapy in appropriate clinical contexts to reduce antibiotic-associated adverse effects.
At a glance
| Generic name | Cessation of antibiotics |
|---|---|
| Also known as | Stop antibiotics |
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Discontinuation of antibiotic therapy permits recovery of commensal bacterial flora that may have been suppressed or eliminated during treatment. This approach aims to minimize collateral damage from prolonged antibiotic exposure, including disruption of the microbiome, selection of resistant organisms, and antibiotic-associated complications such as Clostridioides difficile infection.
Approved indications
- De-escalation or cessation of antibiotic therapy in appropriate clinical contexts to reduce antibiotic-associated adverse effects
Common side effects
- Recurrence or relapse of primary infection
- Clinical deterioration if discontinued prematurely
Key clinical trials
- Folate Treatment to Reduce Death Risk in the Year After Infection-Related Acute Kidney Injury (EARLY_PHASE1)
- Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever (NA)
- Impact of a Simple Automated Best Practice Alert (BPA) on Quantity and Quality of In-hospital Antibiotic Use in a Tertiary and Three Secondary Hospitals (NA)
- Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand
- Hypertonic Saline Inhalation for Mycobacterium Avium Complex Pulmonary Disease (PHASE4)
- PCT Guided Stopping of Antibiotic Therapy in Children With Sepsis (NA)
- Impact of Procalcitonin-guided Algorithm on Early Discontinuation of Antibiotic Therapy (NA)
- Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cessation of antibiotics CI brief — competitive landscape report
- Cessation of antibiotics updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI
Frequently asked questions about Cessation of antibiotics
What is Cessation of antibiotics?
How does Cessation of antibiotics work?
What is Cessation of antibiotics used for?
Who makes Cessation of antibiotics?
Is Cessation of antibiotics also known as anything else?
What development phase is Cessation of antibiotics in?
What are the side effects of Cessation of antibiotics?
Related
- Manufacturer: Brigham and Women's Hospital — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for De-escalation or cessation of antibiotic therapy in appropriate clinical contexts to reduce antibiotic-associated adverse effects
- Also known as: Stop antibiotics
- Compare: Cessation of antibiotics vs similar drugs
- Pricing: Cessation of antibiotics cost, discount & access